Goldman Downgrades BCAX as Call Buyers Push Back

Goldman Sachs just cut Bicara Therapeutics to Sell and slashed its target 60% to $8. The stock has already lost 45% in a week. Yet options traders are betting the other way with unusual conviction.

Why this matters: A Goldman Sachs downgrade to Sell on a clinical-stage biotech with 18.4% of float sold short, 11 days to earnings, and a put-call ratio at its 52-week low creates a rare collision of bearish institutional opinion and aggressively bullish options flow.

Goldman vs the Options Market

The Goldman downgrade landed Thursday morning. Analyst Richard Law cut his rating from Neutral to Sell and lowered his price target from $20 to $8, a 60% reduction. That target sits 18% below Wednesday's close of $9.73. The bear case centres on competitive pressure from petosemtamab, which has a first-to-market advantage in head-and-neck cancer, alongside amivantamab. Even a clean clinical outcome may not translate into commercial traction.

Wedbush moved the same day. David Nierengarten maintained his Outperform but cut his target from $33 to $24, acknowledging the same competitive headwinds while staying constructive on ficerafusp alfa's clinical profile.

Options traders are positioned firmly in the bull camp. The put-call ratio fell to 0.52 on October 29, its lowest print in 52 weeks and 4.15 standard deviations below the 20-day mean of 0.79. That is not a modest tilt toward calls. It is an extreme reading, reflecting concentrated call buying against a backdrop of already-depressed prices.

A Divided Street

BTIG reiterated its Buy rating with a $39 target as recently as October 19. Morgan Stanley had raised its Overweight target to $39 in August. The consensus mean target stands at $34.92, more than three times the current price.

That gap between consensus and the stock price reflects a binary clinical situation. The bull case rests on ficerafusp alfa's 25% complete response rate in first-line HPV-negative head-and-neck cancer and a 31% estimated three-year overall survival rate. Bicara also carries roughly $497 million in cash, funding operations into the first half of 2029. Earnings are due November 10, eleven days away.

Short Interest and the Borrow Market

Short interest sits at 18.4% of the free float, a level noted in the previous article as broadly stable for six weeks. That remains the case. The short score has dropped from 72.4 to 66.9 over the past week, a move consistent with some short covering rather than fresh positioning.

The borrow market is loose. Availability stands at 569%, meaning roughly five and a half shares are available to borrow for every one already on loan. Cost to borrow has risen 68% over the past week to 0.49%, but remains low in absolute terms. Shorts face no supply squeeze.

RA Capital Management holds an 11.5% stake via a Schedule 13D filing, a position last disclosed in March 2026 (stakes are as last disclosed and subject to change without filing once below the 5% threshold).

Data Summary

• Goldman Sachs downgrades to Sell, target cut 60% to $8 from $20
• Wedbush maintains Outperform, cuts target to $24 from $33
• Put-call ratio 0.52, 52-week low, z-score of -4.15 vs 20-day mean
• Short interest 18.4% of free float, short score 66.9, down from 72.4 over five days
• Borrow availability 569%, cost to borrow 0.49%, up 68% week on week
• Earnings due November 10